A 6-Month Extension Study of OTO-104 in Meniere's Disease
NCT02706730
·
clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
189
Enrollment
INDUSTRY
Sponsor class
Stopped
Negative Efficacy Results from the recently completed Phase 3 study 104-201506
Conditions
Meniere's Disease
Interventions
DRUG:
OTO-104
Sponsor
Otonomy, Inc.